Alnylam Pharmaceuticals (ALNY) Holder Bb Biotech Ag Cut Its Holding as Valuation Rose; As Thermo Fisher Scientific (TMO) Share Value Rose, Shareholder Private Wealth Partners Increased Its Holding

January 10, 2018 - By Louis Casey

Bb Biotech Ag decreased its stake in Alnylam Pharmaceuticals Inc. (ALNY) by 9.01% based on its latest 2017Q3 regulatory filing with the SEC. Bb Biotech Ag sold 110,000 shares as the company’s stock rose 48.45% with the market. The institutional investor held 1.11M shares of the health care company at the end of 2017Q3, valued at $130.57 million, down from 1.22M at the end of the previous reported quarter. Bb Biotech Ag who had been investing in Alnylam Pharmaceuticals Inc. for a number of months, seems to be less bullish one the $12.97B market cap company. The stock increased 1.21% or $1.56 during the last trading session, reaching $130.74. About 755,718 shares traded. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has risen 33.54% since January 10, 2017 and is uptrending. It has outperformed by 16.84% the S&P500.

Private Wealth Partners Llc increased its stake in Thermo Fisher Scientific Inc (TMO) by 5.64% based on its latest 2017Q3 regulatory filing with the SEC. Private Wealth Partners Llc bought 4,824 shares as the company’s stock rose 8.13% with the market. The institutional investor held 90,383 shares of the industrial machinery and components company at the end of 2017Q3, valued at $17.10 million, up from 85,559 at the end of the previous reported quarter. Private Wealth Partners Llc who had been investing in Thermo Fisher Scientific Inc for a number of months, seems to be bullish on the $82.65 billion market cap company. The stock increased 1.67% or $3.38 during the last trading session, reaching $206.1. About 1.85M shares traded or 17.76% up from the average. Thermo Fisher Scientific Inc. (NYSE:TMO) has risen 15.57% since January 10, 2017 and is uptrending. It has underperformed by 1.13% the S&P500.

Since September 20, 2017, it had 0 buys, and 3 selling transactions for $23.18 million activity. Greene Barry E also sold $10.66M worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares.

Bb Biotech Ag, which manages about $3.61 billion US Long portfolio, upped its stake in Radius Health Inc. (NASDAQ:RDUS) by 460,000 shares to 5.50 million shares, valued at $211.98M in 2017Q3, according to the filing. It also increased its holding in Incyte Corp. (NASDAQ:INCY) by 153,500 shares in the quarter, for a total of 3.67 million shares, and has risen its stake in Intercept Pharmaceuticals Inc. (NASDAQ:ICPT).

Investors sentiment decreased to 0.92 in 2017 Q3. Its down 0.60, from 1.52 in 2017Q2. It fall, as 30 investors sold ALNY shares while 73 reduced holdings. 40 funds opened positions while 55 raised stakes. 86.02 million shares or 0.72% more from 85.40 million shares in 2017Q2 were reported. Baillie Gifford, a United Kingdom-based fund reported 3.41 million shares. California Pub Employees Retirement Systems holds 0.02% or 133,206 shares in its portfolio. Morgan Stanley has invested 0.03% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Voloridge Investment Mgmt Ltd Liability Corporation invested 0.32% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Arrowmark Colorado Hldg Limited Liability Co reported 0.67% stake. Gotham Asset Mgmt Limited Com has 2,499 shares for 0% of their portfolio. Paloma Prns Mngmt Company holds 0.02% or 13,923 shares in its portfolio. Highbridge Cap Management Lc owns 13,656 shares. Vantage Investment Ltd Com accumulated 155 shares. Natl Bank Of America De owns 74,897 shares. Millennium Mgmt Limited Com stated it has 51,125 shares or 0.01% of all its holdings. Axa reported 40,316 shares or 0.02% of all its holdings. Pictet Asset Management Ltd has 221,628 shares. Arrowstreet Cap Limited Partnership accumulated 0.02% or 51,485 shares. Eventide Asset Ltd Liability Co accumulated 90,000 shares.

Analysts await Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to report earnings on February, 14. They expect $-1.40 earnings per share, down 6.06% or $0.08 from last year’s $-1.32 per share. After $-1.34 actual earnings per share reported by Alnylam Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 4.48% negative EPS growth.

Among 23 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 17 have Buy rating, 1 Sell and 5 Hold. Therefore 74% are positive. Alnylam Pharmaceuticals had 89 analyst reports since August 7, 2015 according to SRatingsIntel. Cowen & Co maintained the stock with “Buy” rating in Thursday, September 7 report. The rating was maintained by Needham with “Buy” on Wednesday, November 16. The stock has “Outperform” rating by Credit Suisse on Wednesday, January 20. The stock has “Buy” rating by Needham on Monday, July 10. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has “Buy” rating given on Monday, June 26 by Cowen & Co. The stock has “Buy” rating by Chardan Capital Markets on Monday, December 19. The rating was upgraded by JP Morgan to “Overweight” on Friday, March 11. JP Morgan maintained the shares of ALNY in report on Friday, August 5 with “Overweight” rating. The firm earned “Buy” rating on Monday, December 11 by FBR Capital. The rating was maintained by Needham with “Buy” on Thursday, October 6.

Private Wealth Partners Llc, which manages about $794.14M and $497.39 million US Long portfolio, decreased its stake in General Electric Co (NYSE:GE) by 48,725 shares to 187,225 shares, valued at $4.53 million in 2017Q3, according to the filing. It also reduced its holding in Pepsico Inc (NYSE:PEP) by 15,350 shares in the quarter, leaving it with 8,950 shares, and cut its stake in Danaher Corp Del (NYSE:DHR).

Among 18 analysts covering Thermo Fisher Scientific (NYSE:TMO), 17 have Buy rating, 0 Sell and 1 Hold. Therefore 94% are positive. Thermo Fisher Scientific had 53 analyst reports since July 24, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Friday, April 28 by Leerink Swann. BTIG Research reinitiated Thermo Fisher Scientific Inc. (NYSE:TMO) rating on Friday, July 22. BTIG Research has “Buy” rating and $180 target. As per Thursday, November 10, the company rating was reinitiated by Leerink Swann. Evercore initiated the shares of TMO in report on Wednesday, January 3 with “Buy” rating. Cowen & Co maintained the stock with “Buy” rating in Wednesday, October 25 report. The rating was initiated by Goldman Sachs with “Buy” on Tuesday, September 26. Leerink Swann maintained the stock with “Outperform” rating in Monday, October 9 report. Jefferies maintained the stock with “Hold” rating in Tuesday, June 6 report. The rating was maintained by Leerink Swann with “Buy” on Monday, December 4. The firm has “Buy” rating by Deutsche Bank given on Thursday, January 7.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.